IP Library Granted Patent US 11,661,593
Granted Patent B2
US 11,661,593 · App. 14/571,670 · Granted May 30, 2023

Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof

Inventors: Meinhard Hasslacher (Vienna, AT); Christian Fiedler (Vienna, AT); Christa Mayer (Wolfsthal, AT); Artur Mitterer (Orth/Donau, AT)
Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
C12N9/6489C12M47/12C12N11/14C12Y304/24087
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,661,593
App. No.
14/571,670
Granted
May 30, 2023
Kind
B2
Abstract

Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange/hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration/diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.

Claims (17)

1. An in vitro method for purifying a therapeutic protein composition, said method comprising:

providing a solution comprising a therapeutic protein;

immobilizing said therapeutic protein on an anion exchange resin or cation exchange resin, wherein said immobilization step is performed in the absence of a solvent-detergent mixture; and

subsequently incubating said immobilized therapeutic protein, with a solvent-detergent mixture at concentrations and for a time period suitable to inactivate a lipid-enveloped virus, wherein said solvent-detergent mixture comprises a non-ionic detergent and an organic solvent;

wherein said method results in a reduction in formation of aggregates of said therapeutic protein as compared to a comparable method, wherein said comparable method comprises incubation with said solvent-detergent mixture while said therapeutic protein is not immobilized, wherein said therapeutic protein is at least one selected from ADAMTS 13 , Factor VIII, Factor VIIa, Factor IX, von Willebrand factor, and anti-MIF antibody.

2. The method according to claim 1 , wherein said solvent-detergent mixture comprises 0.3% Tri-N-butyl phosphate, 0.3% Polysorbate 80, and 1% of a detergent composition comprising octylphenol ethoxylates of general formula:

wherein the average value of N is approximately 9.5.

3. The method according to claim 1 , wherein incubating with said solvent-detergent mixture is from about 30 minutes to about 1 hour.

4. The method according to claim 1 , further comprising eluting said therapeutic protein from said anion exchange resin or cation exchange resin with a storage buffer.

5. The method according to claim 4 , wherein said storage buffer has a pH of greater than 7.0 and comprises less than 10 mM calcium ions, a buffering compound, 0.05% non-ionic detergent, and a salt.

6. The method according to claim 4 , wherein said therapeutic protein is immobilized on the cation exchange resin; and

wherein there is an ultrafiltration, diafiltration, or buffer exchange step subsequent to the eluting step from the cation exchange resin with the storage buffer.

7. The method of claim 1 , wherein said therapeutic protein is immobilized on a cation exchange resin.

8. The method of claim 1 , wherein said therapeutic protein is immobilized on an anion exchange resin.

9. The method of claim 1 , wherein said solvent-detergent mixture comprises at least 0.1% solvent and at least 0.1% detergent.

10. The method of claim 1 , wherein said method results in a reduction of at least about 50% in the formation of aggregates of said therapeutic protein as compared to solvent-detergent treatment while said therapeutic protein is not immobilized.

11. The method of claim 1 , wherein said method results in the formation of at least about 10% less aggregates of said therapeutic protein as compared to solvent-detergent treatment while said therapeutic protein is not immobilized.

Assignments (8)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2022
From: HASSLACHER, MEINHARD; FIEDLER, CHRISTIAN; MAYER, CHRISTA; MITTERER, ARTUR
To: BAXTER INTERNATIONAL INC.; BAXTER HEALTHCARE S.A.
Reel/Frame 061809/0164 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2021
From: BAXALTA GMBH; BAXALTA INCORPORATED
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 055188/0953 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PLEASE REMOVE INCORRECTLY LISTED APPLICATION NOS. 16164208 AND 12437384 PREVIOUSLY RECORDED ON REEL 052461 FRAME 0016. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF ADDRESS. Recorded Jan 8, 2021
From: BAXALTA GMBH
To: BAXALTA GMBH
Reel/Frame 055489/0050 →
CHANGE OF ADDRESS Recorded Feb 7, 2020
From: BAXALTA GMBH
To: BAXALTA GMBH
Reel/Frame 052461/0016 →
CHANGE OF ADDRESS Recorded Oct 30, 2017
From: BAXALTA GMBH
To: BAXALTA GMBH
Reel/Frame 044321/0102 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTIES NAME PREVIOUSLY RECORDED AT REEL: 036360 FRAME: 0001. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 17, 2015
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036621/0554 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER HEALTHCARE S.A.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036360/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 17, 2015
From: BAXTER INTERNATIONAL INC.
To: BAXALTA GMBH; BAXALTA INCORPORATED
Reel/Frame 036373/0426 →
Continuity (3)
Continuation 12847956 · Jul 30, 2010
Provisional Application 61230308 · Jul 31, 2009
Related Publication 20150104849A1 · Apr 16, 2015
Cited By (1)
US 12,492,390